{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:54:29Z","timestamp":1769111669535,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3882,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>We evaluated the tolerability and toxicity attributed to pegylated liposomal doxorubicin (PL\u2010DOX) in women with recurrent or refractory ovarian cancer, and reviewed procedures to prevent or treat toxicity induced by the agent. Medical records of 13 women who received PL\u2010DOX between October 1997 and December 2000 were reviewed. Patients 1\u20138 received PL\u2010DOX once it was added to the hospital formulary in 1997. Patients 9\u201313 received it after medical staff education. Data on premedications, number of cycles, dosage, length of infusion, tolerability, side effects, and indicators for response were collected. The median number of cycles and cumulative dose\/patient of PL\u2010DOX were higher (6 and 420 mg) in the second group than in the first group (2 and 240 mg). Patient factors such as duration of disease and number of chemotherapy cycles influenced tolerability. One patient experienced a life\u2010threatening adverse reaction within minutes of receiving the first dose. Treatment was discontinued, and she was resuscitated successfully. Other dose\u2010 or treatment\u2010limiting complications (neutropenia, stomatitis, plantar\u2010palmar erythrodysesthesia) were documented. Toxicity management consisted of dosage reduction or treatment delay; treatment often was discontinued. Patients with recent disease tolerated more cycles of PL\u2010DOX when given early in recurrence compared with heavily pretreated women with long\u2010standing disease. Tolerability was not necessarily indicative of response. The agent is simple to administer, but its tolerability and lack of uniform toxicity management remain concerns.<\/jats:p>","DOI":"10.1592\/phco.21.7.751.34572","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T09:55:05Z","timestamp":1086947705000},"page":"751-763","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pegylated Liposomal Doxorubicin: Tolerability and Toxicity"],"prefix":"10.1002","volume":"21","author":[{"given":"Adrian L.","family":"Goram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry L.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Doxil (doxorubicin) product monograph","author":"Alza Pharmaceuticals, Inc.","year":"1999"},{"issue":"1","key":"e_1_2_1_3_2","first-page":"8","article-title":"Treatment of refractory and recurrent ovarian cancer","volume":"26","author":"Alberts D.S.","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_1_4_2","first-page":"905","volume-title":"AHFS drug information 2000","author":"American Society of Health\u2010System Pharmacists","year":"2000"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700544-00007"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200009000-00016"},{"issue":"7","key":"e_1_2_1_7_2","first-page":"24","article-title":"Innovative therapies for advanced ovarian cancer","volume":"27","author":"Trimble E.L.","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_1_8_2","unstructured":"RestinoM.Pharmacy update. FDA actions. Novations NewsletterJune 11 1999."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<85::AID-AJH16>3.0.CO;2-8"},{"key":"e_1_2_1_10_2","first-page":"393A","article-title":"Clinical use of liposomal doxorubicin (LD) in platinum\u2010refractory ovarian cancer (PROC): predictors of response in pre\u2010treated patients [abstr]","volume":"19","author":"Hensley M.","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.987"},{"key":"e_1_2_1_12_2","first-page":"72A","article-title":"Prevention and management of Doxil\u2010related side effects: basic strategies [abstr]","volume":"17","author":"Yee S.","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_13_2","first-page":"217A","article-title":"Apparent protection of Doxil skin and oral toxicities when combined with cisplatin (CDDP): results of a phase I study [abstr]","volume":"18","author":"Klein P.","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_14_2","first-page":"206A","article-title":"Pegylated liposomal doxorubicin (Doxil) reduced clinical cardiotoxicity in patients reaching or exceeding 500 mg\/m2 cumulative doses of Doxil [abstr]","volume":"19","author":"Safra T.","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_15_2","volume-title":"Safety assessment: Doxil (doxorubicin HC liposome injection) in refractory AIDS\u2010relate Kaposi's sarcoma","author":"Dezube B.J.","year":"1996"},{"key":"e_1_2_1_16_2","unstructured":"HerzogT.J. GandhiS. SwisherE.M. et al.Liposomal doxorubicin in advanced relapsed gynecologic malignancies. Presented at the 30th annual meeting of the Society of Gynecologic Oncologists San Francisco March 2024 1999."},{"key":"e_1_2_1_17_2","unstructured":"Anonymous.Lysine monograph. Natural medicines comprehensive database. Available fromhttp:www.naturaldatabase.com. Accessed April 14 2000."},{"key":"e_1_2_1_18_2","first-page":"545","volume-title":"Natural medicines comprehensive database","author":"Jellin J.M.","year":"1999"},{"key":"e_1_2_1_19_2","first-page":"360A","article-title":"Interim analysis of a non\u2010comparative, multicenter, study of Doxil\/Caelyx in the treatment of patients with refractory ovarian cancer [abstr]","volume":"18","author":"Rose P.","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_20_2","first-page":"371A","article-title":"A retrospective analysis of the clinical utility of Doxil in recurrent ovarian cancer (ROC) [abstr]","volume":"18","author":"Campos S.M.","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199801000-00005"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-6-798"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H"},{"key":"e_1_2_1_24_2","first-page":"82A","article-title":"Prevention of palmar\u2010plantar erythrodysesthesia associated with liposome\u2010encapsulated doxorubicin (Doxil) by oral dexamethasone [abstr]","volume":"16","author":"Titgan M.A.","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216925"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-8-688"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02994097"},{"issue":"5","key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/001857879903400512","article-title":"Pyridoxine for hand\u2010foot syndrome","volume":"34","author":"Patel J.S.","year":"1999","journal-title":"Hosp Pharm"},{"issue":"10","key":"e_1_2_1_29_2","first-page":"265b","article-title":"Efficacy of pyridoxine to ameliorate cutaneous toxicity associated with Doxil [abstr]","volume":"92","author":"Hussein M.A.","year":"1998","journal-title":"Proc Am Soc Hematol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050981"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.7.751.34572","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.7.751.34572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:53:16Z","timestamp":1761065596000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.7.751.34572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1592\/phco.21.7.751.34572"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.7.751.34572","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}